Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.

Caron J, Pène V, Tolosa L, Villaret M, Luce E, Fourrier A, Heslan JM, Saheb S, Bruckert E, Gómez-Lechón MJ, Nguyen TH, Rosenberg AR, Weber A, Dubart-Kupperschmitt A.

Stem Cell Res Ther. 2019 Jul 29;10(1):221. doi: 10.1186/s13287-019-1342-6.

2.

Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent stem cells-derived hepatic stem cells.

Fourrier A, Delbos F, Menoret S, Collet C, Thi Thuy LT, Myara A, Petit F, Tolosa L, Laplanche S, Gómez-Lechón MJ, Labrune P, Anegon I, Vallier L, Garnier D, Nguyen TH.

Xenotransplantation. 2019 Jul 25:e12544. doi: 10.1111/xen.12544. [Epub ahead of print]

PMID:
31342573
3.

Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes.

Tolosa L, Jiménez N, Pelechá M, Castell JV, Gómez-Lechón MJ, Donato MT.

Arch Toxicol. 2019 Feb;93(2):519-532. doi: 10.1007/s00204-018-2349-y. Epub 2018 Nov 13.

PMID:
30426164
4.

Assessment of the cytotoxic potential of an aqueous-ethanolic extract from Thalassia testudinum angiosperm marine grown in the Caribbean Sea.

Rodeiro I, Hernández I, Herrera JA, Riera M, Donato MT, Tolosa L, González K, Ansoar Y, Gómez-Lechón MJ, Vanden Berghe W, Lopes M.

J Pharm Pharmacol. 2018 Nov;70(11):1553-1560. doi: 10.1111/jphp.13001. Epub 2018 Aug 30.

PMID:
30159909
5.

Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems.

Fernández-Murga ML, Petrov PD, Conde I, Castell JV, Goméz-Lechón MJ, Jover R.

Food Chem Toxicol. 2018 Oct;120:196-212. doi: 10.1016/j.fct.2018.07.017. Epub 2018 Jul 7. Review.

PMID:
29990576
6.

Predicting drug-induced cholestasis: preclinical models.

Petrov PD, Fernández-Murga ML, López-Riera M, Goméz-Lechón MJ, Castell JV, Jover R.

Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):721-738. doi: 10.1080/17425255.2018.1487399. Epub 2018 Jun 20. Review.

PMID:
29888962
7.

In vitro modulation of the cytochrome P450 and ABCB1/P-glycoprotein activities of the aqueous extract of Allophylus cominia (L) Sw. leaves.

Pérez CL, Donato MT, Hernández I, Paz Lopes MT, Marrero E, Herrera JA, Gómez-Lechón MJ, Rodeiro I.

Drug Metab Pers Ther. 2017 Dec 20;32(4):201-208. doi: 10.1515/dmpt-2017-0020.

PMID:
29176019
8.

Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.

Tolosa L, Jiménez N, Pérez G, Castell JV, Gómez-Lechón MJ, Donato MT.

Arch Toxicol. 2018 Jan;92(1):383-399. doi: 10.1007/s00204-017-2036-4. Epub 2017 Jul 31.

9.

A Multi-Parametric Fluorescent Assay for the Screening and Mechanistic Study of Drug-Induced Steatosis in Liver Cells in Culture.

Tolosa L, Gómez-Lechón MJ, Donato MT.

Curr Protoc Toxicol. 2017 May 2;72:14.15.1-14.15.11. doi: 10.1002/cptx.20.

PMID:
28463417
10.

New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease.

López-Riera M, Conde I, Tolosa L, Zaragoza Á, Castell JV, Gómez-Lechón MJ, Jover R.

Front Pharmacol. 2017 Jan 25;8:3. doi: 10.3389/fphar.2017.00003. eCollection 2017.

11.

Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.

Donato MT, Gómez-Lechón MJ, Tolosa L.

Expert Opin Drug Discov. 2017 Feb;12(2):201-211. doi: 10.1080/17460441.2017.1271784. Epub 2016 Dec 21. Review.

PMID:
27936962
12.

Alternative Cell Sources to Adult Hepatocytes for Hepatic Cell Therapy.

Pareja E, Gómez-Lechón MJ, Tolosa L.

Methods Mol Biol. 2017;1506:17-42.

PMID:
27830543
13.

Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to develop new predictive biomarkers for early drug development.

Donato MT, López-Riera M, Castell JV, Gómez-Lechón MJ, Jover R.

Toxicol Lett. 2016 Nov 30;263:58-67. doi: 10.1016/j.toxlet.2016.10.008. Epub 2016 Oct 17.

PMID:
27765674
14.

Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.

Gómez-Lechón MJ, Tolosa L, Donato MT.

Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):137-148. doi: 10.1080/17425255.2017.1238459. Epub 2016 Sep 27. Review.

PMID:
27671376
15.

Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?

Tolosa L, Pareja E, Gómez-Lechón MJ.

Transplantation. 2016 Dec;100(12):2548-2557. Review.

PMID:
27495745
16.

Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening.

Gómez-Lechón MJ, Tolosa L.

Arch Toxicol. 2016 Sep;90(9):2049-2061. doi: 10.1007/s00204-016-1756-1. Epub 2016 Jun 20. Review.

PMID:
27325232
17.

Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing.

Tolosa L, Gómez-Lechón MJ, López S, Guzmán C, Castell JV, Donato MT, Jover R.

Toxicol Sci. 2016 Jul;152(1):214-29. doi: 10.1093/toxsci/kfw078. Epub 2016 May 4.

PMID:
27208088
18.

Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis.

Tolosa L, Gómez-Lechón MJ, Jiménez N, Hervás D, Jover R, Donato MT.

Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.

PMID:
27089845
19.

Hepatocyte transplantation program: Lessons learned and future strategies.

Ibars EP, Cortes M, Tolosa L, Gómez-Lechón MJ, López S, Castell JV, Mir J.

World J Gastroenterol. 2016 Jan 14;22(2):874-86. doi: 10.3748/wjg.v22.i2.874. Review.

20.

Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.

Gómez-Lechón MJ, Tolosa L, Donato MT.

J Appl Toxicol. 2016 Jun;36(6):752-68. doi: 10.1002/jat.3277. Epub 2015 Dec 22. Review.

PMID:
26691983
21.

Transplantation of hESC-derived hepatocytes protects mice from liver injury.

Tolosa L, Caron J, Hannoun Z, Antoni M, López S, Burks D, Castell JV, Weber A, Gomez-Lechon MJ, Dubart-Kupperschmitt A.

Stem Cell Res Ther. 2015 Dec 12;6:246. doi: 10.1186/s13287-015-0227-6.

22.

General Cytotoxicity Assessment by Means of the MTT Assay.

Tolosa L, Donato MT, Gómez-Lechón MJ.

Methods Mol Biol. 2015;1250:333-48. doi: 10.1007/978-1-4939-2074-7_26.

PMID:
26272156
23.

Culture and Functional Characterization of Human Hepatoma HepG2 Cells.

Donato MT, Tolosa L, Gómez-Lechón MJ.

Methods Mol Biol. 2015;1250:77-93. doi: 10.1007/978-1-4939-2074-7_5.

PMID:
26272135
24.

LC-MS untargeted metabolomic analysis of drug-induced hepatotoxicity in HepG2 cells.

García-Cañaveras JC, Jiménez N, Gómez-Lechón MJ, Castell JV, Donato MT, Lahoz A.

Electrophoresis. 2015 Sep;36(18):2294-2302. doi: 10.1002/elps.201500095. Epub 2015 Jul 22.

PMID:
26031481
25.

Human neonatal hepatocyte transplantation induces long-term rescue of unconjugated hyperbilirubinemia in the Gunn rat.

Tolosa L, López S, Pareja E, Donato MT, Myara A, Nguyen TH, Castell JV, Gómez-Lechón MJ.

Liver Transpl. 2015 Jun;21(6):801-11. doi: 10.1002/lt.24121.

26.

High-content screening technology for studying drug-induced hepatotoxicity in cell models.

Tolosa L, Gómez-Lechón MJ, Donato MT.

Arch Toxicol. 2015 Jul;89(7):1007-22. doi: 10.1007/s00204-015-1503-z. Epub 2015 Mar 19. Review.

PMID:
25787152
27.

Competency of different cell models to predict human hepatotoxic drugs.

Gómez-Lechón MJ, Tolosa L, Conde I, Donato MT.

Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1553-68. doi: 10.1517/17425255.2014.967680. Epub 2014 Oct 9. Review.

PMID:
25297626
28.

Apicobasal polarity controls lymphocyte adhesion to hepatic epithelial cells.

Reglero-Real N, Álvarez-Varela A, Cernuda-Morollón E, Feito J, Marcos-Ramiro B, Fernández-Martín L, Gómez-Lechón MJ, Muntané J, Sandoval P, Majano PL, Correas I, Alonso MA, Millán J.

Cell Rep. 2014 Sep 25;8(6):1879-1893. doi: 10.1016/j.celrep.2014.08.007. Epub 2014 Sep 18.

29.

High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins.

Tolosa L, Carmona A, Castell JV, Gómez-Lechón MJ, Donato MT.

Arch Toxicol. 2015 Oct;89(10):1847-60. doi: 10.1007/s00204-014-1334-3. Epub 2014 Aug 27.

PMID:
25160661
30.

In vitro/in vivo screening of oxidative homeostasis and damage to DNA, protein, and lipids using UPLC/MS-MS.

Carretero A, León Z, García-Cañaveras JC, Zaragoza A, Gómez-Lechón MJ, Donato MT, Lahoz A.

Anal Bioanal Chem. 2014 Sep;406(22):5465-76. doi: 10.1007/s00216-014-7983-5. Epub 2014 Jun 27.

PMID:
24969468
31.

A simple transcriptomic signature able to predict drug-induced hepatic steatosis.

Benet M, Moya M, Donato MT, Lahoz A, Hervás D, Guzmán C, Gómez-Lechón MJ, Castell JV, Jover R.

Arch Toxicol. 2014 Apr;88(4):967-82. doi: 10.1007/s00204-014-1197-7. Epub 2014 Jan 28.

PMID:
24469900
32.
33.

[Current status and future perspectives of hepatocyte transplantation].

Pareja E, Cortés M, Gómez-Lechón MJ, Maupoey J, San Juan F, López R, Mir J.

Cir Esp. 2014 Feb;92(2):74-81. doi: 10.1016/j.ciresp.2013.04.010. Epub 2013 Sep 3. Review. Spanish.

PMID:
24007980
34.

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG.

Arch Toxicol. 2013 Aug;87(8):1315-530. doi: 10.1007/s00204-013-1078-5. Epub 2013 Aug 23. Review.

35.

[Liver cell therapy in the treatment of inborn errors of metabolism in children].

Pareja E, Ribes C, Gómez-Lechón MJ, Cortes M, Vila JJ, Dalmau J, Ibáñez V, Polo B, Castell JV, Mir J.

An Pediatr (Barc). 2013 Dec;79(6):390.e1-8. doi: 10.1016/j.anpedi.2013.05.018. Epub 2013 Jul 27. Review. Spanish.

36.

Neonatal livers: a source for the isolation of good-performing hepatocytes for cell transplantation.

Tolosa L, Pareja-Ibars E, Donato MT, Cortés M, López S, Jiménez N, Mir J, Castell JV, Gómez-Lechón MJ.

Cell Transplant. 2014;23(10):1229-42. doi: 10.3727/096368913X669743. Epub 2013 Jun 25.

PMID:
23803290
37.

Human hepatocyte transplantation in patients with hepatic failure awaiting a graft.

Pareja E, Gomez-Lechon MJ, Cortes M, Bonora-Centelles A, Castell JV, Mir J.

Eur Surg Res. 2013;50(3-4):273-81. doi: 10.1159/000351332. Epub 2013 Jun 18.

PMID:
23796722
38.

Multiparametric evaluation of the cytoprotective effect of the Mangifera indica L. stem bark extract and mangiferin in HepG2 cells.

Tolosa L, Rodeiro I, Donato MT, Herrera JA, Delgado R, Castell JV, Gómez-Lechón MJ.

J Pharm Pharmacol. 2013 Jul;65(7):1073-82. doi: 10.1111/jphp.12071. Epub 2013 Apr 26.

PMID:
23738735
39.

Fluorescence-based screening of cytochrome P450 activities in intact cells.

Donato MT, Gómez-Lechón MJ.

Methods Mol Biol. 2013;987:135-48. doi: 10.1007/978-1-62703-321-3_12.

PMID:
23475674
40.

HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.

Tolosa L, Gómez-Lechón MJ, Pérez-Cataldo G, Castell JV, Donato MT.

Arch Toxicol. 2013 Jun;87(6):1115-27. doi: 10.1007/s00204-013-1012-x. Epub 2013 Feb 9.

PMID:
23397584
41.

Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases.

Ribes-Koninckx C, Ibars EP, Calzado Agrasot MÁ, Bonora-Centelles A, Miquel BP, Vila Carbó JJ, Aliaga ED, Pallardó JM, Gómez-Lechón MJ, Castell JV.

Cell Transplant. 2012;21(10):2267-82. doi: 10.3727/096368912X637505.

PMID:
23231960
42.

miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle.

Pérez-Andreu V, Teruel R, Corral J, Roldán V, García-Barberá N, Salloum-Asfar S, Gómez-Lechón MJ, Bourgeois S, Deloukas P, Wadelius M, Vicente V, González-Conejero R, Martínez C.

Mol Med. 2013 Jan 22;18:1466-72. doi: 10.2119/molmed.2012.00062.

43.

Comparative analysis of eight cytotoxicity assays evaluated within the ACuteTox Project.

Clothier R, Gómez-Lechón MJ, Kinsner-Ovaskainen A, Kopp-Schneider A, O'Connor JE, Prieto P, Stanzel S.

Toxicol In Vitro. 2013 Jun;27(4):1347-56. doi: 10.1016/j.tiv.2012.08.015. Epub 2012 Aug 23.

PMID:
22951948
44.

An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.

Lahoz A, Vilà MR, Fabre M, Miquel JM, Rivas M, Maines J, Castell JV, Gómez-Lechón MJ.

Toxicol In Vitro. 2013 Jun;27(4):1410-5. doi: 10.1016/j.tiv.2012.08.001. Epub 2012 Aug 13.

PMID:
22910125
45.

Evaluation of genotoxicity and DNA protective effects of mangiferin, a glucosylxanthone isolated from Mangifera indica L. stem bark extract.

Rodeiro I, Hernandez S, Morffi J, Herrera JA, Gómez-Lechón MJ, Delgado R, Espinosa-Aguirre JJ.

Food Chem Toxicol. 2012 Sep;50(9):3360-6. doi: 10.1016/j.fct.2012.06.032. Epub 2012 Jun 27.

PMID:
22749943
46.

Drug-induced liver steatosis and phospholipidosis: cell-based assays for early screening of drug candidates.

Donato MT, Gómez-Lechón MJ.

Curr Drug Metab. 2012 Oct;13(8):1160-73. Review.

PMID:
22746303
47.

Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs.

Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O'Connor JE, Gómez-Lechón MJ.

Toxicol Sci. 2012 May;127(1):187-98. doi: 10.1093/toxsci/kfs083. Epub 2012 Feb 13.

PMID:
22331495
48.

Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment.

Tolosa L, Donato MT, Pérez-Cataldo G, Castell JV, Gómez-Lechón MJ.

Toxicol In Vitro. 2012 Dec;26(8):1272-7. doi: 10.1016/j.tiv.2011.11.008. Epub 2011 Nov 25.

PMID:
22138474
49.

High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay.

Donato MT, Tolosa L, Jiménez N, Castell JV, Gómez-Lechón MJ.

J Biomol Screen. 2012 Mar;17(3):394-400. doi: 10.1177/1087057111427586. Epub 2011 Nov 23.

PMID:
22116976
50.

Evaluation of cytochrome P450 activities in human hepatocytes in vitro.

Gómez-Lechón MJ, Lahoz A, Castell JV, Donato MT.

Methods Mol Biol. 2012;806:87-97. doi: 10.1007/978-1-61779-367-7_7.

PMID:
22057447

Supplemental Content

Loading ...
Support Center